Melanotan II (MT-2)

Melanotan II is a synthetic melanocortin peptide built by taking the essential core of the natural hormone α-MSH and closing it into a ring. Rather than a linear chain of thirteen residues, it is a cyclic seven-residue molecule in which two positions are bonded to one another, locking the peptide into a fixed shape.

Cyclisation is the defining feature and explains most of what follows. A linear peptide is flexible and spends much of its time in shapes no receptor recognises; holding it in one conformation makes binding far more efficient and leaves fewer loose ends for enzymes to attack. The trade-off is selectivity. The locked shape fits several members of the melanocortin receptor family, so this compound engages a broader set of targets than its more selective counterpart.

That breadth is the reason it occupies a separate place in research. Because the melanocortin family spans pigmentation, inflammation, energy balance and central nervous system signalling, a non-selective agonist produces effects across several systems at once — informative when the question is about the family, a confounder when it is about one receptor.

• Cyclic peptide design: It is one of the standard demonstrations that closing a peptide into a ring raises potency and durability at the cost of selectivity. That trade-off is a central problem in peptide chemistry and this molecule illustrates it cleanly.

• Receptor family breadth: Activity across MC1, MC3, MC4 and MC5 makes it a tool for probing what the family does collectively, rather than for isolating one member — which is a legitimate experimental aim in its own right.

• Central melanocortin signalling: MC4 receptors sit in brain regions governing appetite and arousal, and much of the interest in this peptide concerns central rather than skin effects, in contrast to the more selective analogue.

• A parent compound: Its breakdown product became a compound in its own right, developed for MC4 signalling. Tracing that lineage is a documented example of how a research peptide gives rise to a more selective successor.

Receptors work by shape. A signalling molecule fits into a binding site the way a key fits a lock, and a flexible molecule is a key that keeps bending — most of the time it is in a shape that will not turn. Cyclising a peptide fixes the shape permanently, so every encounter with the receptor is a productive one. That is why ring-closed peptides are typically much more potent than their linear equivalents.

The cost appears when the lock has close relatives. The five melanocortin receptors are structurally similar, and a molecule held in a shape that fits one tends to fit the others too. Melanotan II accordingly signals at receptors on pigment cells, on immune cells and in the brain. In an intact organism these responses overlap, which is precisely why the more selective analogue exists.

The central effects are the ones that separate it from a pigmentation compound. MC4 receptors are concentrated in the hypothalamus, the brain region that coordinates appetite, energy use and arousal. A molecule reaching the brain and engaging that receptor is being studied as a neuroscience compound, not a skin one, and its research literature reflects that division.

The receptor pharmacology is solid: binding profiles across the melanocortin subtypes have been characterised repeatedly, and its greater potency and lower selectivity relative to the linear analogue are not in dispute. Its value as a laboratory probe rests on that characterisation.

It has never been approved as a medicine, development was not completed, and it is supplied for laboratory research only. Because it acts across several melanocortin receptors at once, whole-organism findings are harder to attribute to any one of them. That breadth is also why it is used: where the question is about the receptor family rather than a single member, a non-selective agonist is the right instrument.

Melanotan I is the natural comparison — a linear, MC1-preferring analogue with a completed clinical development programme behind it. Where this compound is broad, that one is narrow, and choosing between them is usually the first decision in designing a melanocortin experiment.

PT-141 is Melanotan II's own metabolite, isolated and developed as a distinct compound for central MC4 signalling. The relationship is direct and worth knowing: one of these molecules is what the other becomes.